Abstract
Biochemical modulation involves the use of one drug (modulating agent; modulator) to change the pharmacokinetics and/or pharmacodynamics of a cytotoxic agent (effector), in a way that the therapeutic index of the effector is enhanced [1]. The modulator is often also a cytotoxic agent, but a non-cytotoxic agent like leucovorin is sometimes used as well. The modulating agent improves selectivity or sensitivity of an effector and decreases its toxicity to normal cells via a biochemical or metabolical mechanism. Currently, several biochemical modulations such as the sequential methotrexate (MTX)/5-fluorouracil (5-FU), leucovorin (LV)/5-FU, and cisplatin (CDDP)/5-FU have been evaluated clinically in terms of their efficacy for alimentary tract malignancies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Howell SB (1986) Biochemical modulation: Current status and considerations for the future. In: Kimura K, Yamada K, Krakoff IH, Carter SK (eds) Cancer Chemotherapy—challenges for the future. Excerpta Medica, pp 108–116
Scanlon KJ, Newman EM, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923–8925
O’Dwyer PJ, Cornfeld MJ, Peter R, Comis RL (1990) Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. Cancer Chemother Pharmacol 27: 131–134
Vokes EE, Choi KE, Schilsky RL, Moran WJ, Guarnieri CM, Weichselbaum RR, Panje WR (1988) Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6: 618–626
Clark J, Dreyfuss A, Norris C, Busse P, Miller D, Lucarini J, Andersen J, Casey D, Frei E (1990) Continuous infusion cisplatin, 5-FU and high-dose leucovorin (PEL): favorable early results as induction therapy for squamous cell carcinoma of the head and neck. Proc ASCO 9: 172
Browman GP, Archibald SD, Young JEM, Hryniuk WM, Russell R, Kiehl K, Levine MN (1983) Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol 1: 787–792
Hayashi K, Ide H, Shinoda M, Fukushima M (1992) Phase II study of cisplatin (CDDP) plus 5-fluorouracil (5-FU) and leucovorin ( LCV) for squamous cell carcinoma of the esophagus. Proc ASCO 11: 178
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Tokyo
About this paper
Cite this paper
Konishi, T. et al. (1993). Leucovorin, Cisplatin, and 5-Fluorouracil for Advanced Esophageal Cancer. In: Nabeya, Ki., Hanaoka, T., Nogami, H. (eds) Recent Advances in Diseases of the Esophagus. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68246-2_136
Download citation
DOI: https://doi.org/10.1007/978-4-431-68246-2_136
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68248-6
Online ISBN: 978-4-431-68246-2
eBook Packages: Springer Book Archive